Pharmaceutical & MedTech: Edging Toward Normalcy

Published on 11 Feb, 2021

Download this report:     Pharmaceutical & MedTech: Edging Toward Normalcy

Healthcare, like other sectors, was hit by COVID-19 in 2020. This especially holds true for the pharmaceutical and MedTech sub-sectors in healthcare that were impacted in 2Q20, reflected in the weak performance of companies in these domains. However, both sub-sectors recovered in 3Q20, with the relaxation of social restrictions and strong pick-up in demand for COVID-19-related antibodies and products. The outlook for both sub-sectors is positive; however, continuation of the pandemic and policy changes in countries of operation could pose risks.